FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2969362972> ?p ?o ?g. }

• W2969362972 endingPage "e0221511" @default.
• W2969362972 startingPage "e0221511" @default.
• W2969362972 abstract "Introduction Long-term treatment is used in patients with osteoporosis, and bisphosphonates (BPs) are the most commonly prescribed medications. However, in some patients this therapy is not effective, cause different side effects and complications. Unfortunately, at least one year is needed to identify and confirm an ineffectiveness of BPs therapy on bone mineral density (BMD). Among other factors, a response to BPs therapy may also be explained by genetic factors. The aim of this study was to analyze the influence of SOST, PTH, FGF2, FDPS, GGPS1, and LRP5 gene variants on the response to treatment with aminobisphosphonates. Materials and methods Women with postmenopausal osteoporosis were included to this study if they used aminobisphosphonates for at least 12 months. Exclusion criteria were: persistence on BPs therapy less than 80%, bone metabolic diseases, diseases deemed to affect bone metabolism, malignant tumours, using of any medications influencing BMD. The study protocol was approved by the local ethics committee. The BMD at the lumbar spine and femoral neck were measured using dual x-ray absorptiometry (GE Lunar) before and at least 12 months after treatment with BPs. According to BMD change, patients were divided in two groups–responders and non-responders to BPs terapy. Polymorphic variants in SOST, PTH, FGF2, FDPS, GGPS1, and LRP5 genes were determined using PCR analysis with TaqMan probes (Thermo Scientific). Results In total, 201 women with BPs therapy were included in the study. No statistically significant differences were observed in age, age at menopause, weight, height, BMI and baseline BMD levels between responders (122 subjects) and non-responders (79 subjects). As single markers, the SOST rs1234612 T/T (OR = 2.3; P = 0.02), PTH rs7125774 T/T (OR = 2.8, P = 0.0009), FDPS rs2297480 G/G (OR = 29.3, P = 2.2×10−7), and GGPS1 rs10925503 C/C+C/T (OR = 2.9; P = 0.003) gene variants were over-represented in non-responders group. No significant association between FGF2 rs6854081 and LRP5 rs3736228 gene variants and response to BPs treatment was observed. The carriers of T-T-G-C allelic combination (constructed from rs1234612, rs7125774, rs2297480, and rs10925503) were predisposed to negative response to BPs treatment (OR = 4.9, 95% CI 1.7–14.6, P = 0.005). The C-C-T-C combination was significantly over-represented in responders (OR = 0.1, 95% CI 0.1–0.5, P = 0.006). Conclusions Our findings highlight the importance of identified single gene variants and their allelic combinations for pharmacogenetics of BPs therapy of osteoporosis. Complex screening of these genetic markers could be used as a new strategy for personalized antiresorptive therapy." @default.
• W2969362972 created "2019-08-29" @default.
• W2969362972 creator A5001173705 @default.
• W2969362972 creator A5007125037 @default.
• W2969362972 creator A5013186684 @default.
• W2969362972 creator A5025964847 @default.
• W2969362972 creator A5039858248 @default.
• W2969362972 creator A5040910868 @default.
• W2969362972 creator A5053214721 @default.
• W2969362972 creator A5064593515 @default.
• W2969362972 creator A5081708343 @default.
• W2969362972 creator A5051140614 @default.
• W2969362972 date "2019-08-22" @default.
• W2969362972 modified "2023-10-17" @default.
• W2969362972 title "Bone metabolism genes variation and response to bisphosphonate treatment in women with postmenopausal osteoporosis" @default.
• W2969362972 cites W1515463409 @default.
• W2969362972 cites W1875277064 @default.
• W2969362972 cites W1965168774 @default.
• W2969362972 cites W1973028457 @default.
• W2969362972 cites W1976967162 @default.
• W2969362972 cites W1988892013 @default.
• W2969362972 cites W1995846491 @default.
• W2969362972 cites W1996838604 @default.
• W2969362972 cites W2000033313 @default.
• W2969362972 cites W2001865334 @default.
• W2969362972 cites W2009699689 @default.
• W2969362972 cites W2024143452 @default.
• W2969362972 cites W2094716322 @default.
• W2969362972 cites W2099244701 @default.
• W2969362972 cites W2101577087 @default.
• W2969362972 cites W2106406207 @default.
• W2969362972 cites W2111000907 @default.
• W2969362972 cites W2113958163 @default.
• W2969362972 cites W2129706407 @default.
• W2969362972 cites W2129844439 @default.
• W2969362972 cites W2135176380 @default.
• W2969362972 cites W2147773269 @default.
• W2969362972 cites W2171709369 @default.
• W2969362972 cites W2176559083 @default.
• W2969362972 cites W2302688695 @default.
• W2969362972 cites W2314030751 @default.
• W2969362972 cites W2317743333 @default.
• W2969362972 cites W2343182584 @default.
• W2969362972 cites W2417147833 @default.
• W2969362972 cites W2591241162 @default.
• W2969362972 cites W2807467795 @default.
• W2969362972 cites W2894914335 @default.
• W2969362972 cites W4250875619 @default.
• W2969362972 cites W4252350389 @default.
• W2969362972 doi "https://doi.org/10.1371/journal.pone.0221511" @default.
• W2969362972 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6705789" @default.
• W2969362972 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/31437227" @default.
• W2969362972 hasPublicationYear "2019" @default.
• W2969362972 type Work @default.
• W2969362972 sameAs 2969362972 @default.
• W2969362972 citedByCount "18" @default.
• W2969362972 countsByYear W29693629722019 @default.
• W2969362972 countsByYear W29693629722020 @default.
• W2969362972 countsByYear W29693629722021 @default.
• W2969362972 countsByYear W29693629722022 @default.
• W2969362972 countsByYear W29693629722023 @default.
• W2969362972 crossrefType "journal-article" @default.
• W2969362972 hasAuthorship W2969362972A5001173705 @default.
• W2969362972 hasAuthorship W2969362972A5007125037 @default.
• W2969362972 hasAuthorship W2969362972A5013186684 @default.
• W2969362972 hasAuthorship W2969362972A5025964847 @default.
• W2969362972 hasAuthorship W2969362972A5039858248 @default.
• W2969362972 hasAuthorship W2969362972A5040910868 @default.
• W2969362972 hasAuthorship W2969362972A5051140614 @default.
• W2969362972 hasAuthorship W2969362972A5053214721 @default.
• W2969362972 hasAuthorship W2969362972A5064593515 @default.
• W2969362972 hasAuthorship W2969362972A5081708343 @default.
• W2969362972 hasBestOaLocation W29693629721 @default.
• W2969362972 hasConcept C126322002 @default.
• W2969362972 hasConcept C134018914 @default.
• W2969362972 hasConcept C143998085 @default.
• W2969362972 hasConcept C170033053 @default.
• W2969362972 hasConcept C2775854910 @default.
• W2969362972 hasConcept C2776541429 @default.
• W2969362972 hasConcept C2776886416 @default.
• W2969362972 hasConcept C2777251235 @default.
• W2969362972 hasConcept C2778562196 @default.
• W2969362972 hasConcept C71924100 @default.
• W2969362972 hasConceptScore W2969362972C126322002 @default.
• W2969362972 hasConceptScore W2969362972C134018914 @default.
• W2969362972 hasConceptScore W2969362972C143998085 @default.
• W2969362972 hasConceptScore W2969362972C170033053 @default.
• W2969362972 hasConceptScore W2969362972C2775854910 @default.
• W2969362972 hasConceptScore W2969362972C2776541429 @default.
• W2969362972 hasConceptScore W2969362972C2776886416 @default.
• W2969362972 hasConceptScore W2969362972C2777251235 @default.
• W2969362972 hasConceptScore W2969362972C2778562196 @default.
• W2969362972 hasConceptScore W2969362972C71924100 @default.
• W2969362972 hasFunder F4320309920 @default.
• W2969362972 hasIssue "8" @default.
• W2969362972 hasLocation W29693629721 @default.
• W2969362972 hasLocation W29693629722 @default.
• W2969362972 hasLocation W29693629723 @default.

• next